PAPLN

Across TCGA pan-cancer cohorts, PAPLN mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PAPLN data layer compared with 23 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher PAPLN mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated PAPLN expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

PDAC, LUAD, and GBM are the cancer types where PAPLN mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.897	0.696	.003	52	view →
LUAD	DFS	Median	All	0.889	0.442	.001	21	view →
GBM	OS	Quartile	All	0.373	0.638	.017	9	view →
CCRCC	OS	Median	All	0.935	0.745	.006	6	view →
UCEC	OS	Quartile	II,III,IV	0.520	1.000	.033	4	view →
HNSC	OS	Quartile	II,III,IV	0.921	1.000	.027	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

PAPLN–PDAC (DFS)

Open the PDAC breakdown →